Bausch Health Companies Inc. (BHC): one to watch?

A real turnaround is underway, but $20.8B of debt and a 2028 patent cliff on its top drug make this a speculative bet, not a clear bargain.

👀 WATCH Fundamentals63/100

Down 97% from its all-time high of $257.53 — now $7.00

Why BHC dropped

This isn't a fresh crash — BHC has been a broken stock since 2015 due to a debt-fueled roll-up strategy (Valeant era) that left it drowning in leverage; it just jumped 26-27% after beating Q2 2026 earnings and raising guidance, its 13th straight quarter of growth.

Fwd P/E 1.7Op margin 27.2%Rev growth 12.7%Debt/equity —Analyst upside 7.1%

How this scored 63/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Loss-making today, but operations are profitable (27.2%) and analysts expect positive earnings next year

✅ Generates cash Free cash flow $1.4B

✅ Not drowning in debt Debt/equity unknown (limit 200%)

✅ Can pay its bills Current ratio 1.4 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 11/25

Operating margin 27.2% 9/9

Net profit margin -10.1% 0/8

Return on equity unknown 2/8

Growth Is it getting bigger, or dying? 21/25

Revenue growth 12.7% 5/9

Earnings growth 70.4% 8/8

Expected profit change 236.8% 8/8

Value Is it cheap right now? 19/25

Forward P/E 1.7 10/10

PEG ratio 0.0 8/8

Analyst target upside 7.1% 1/7

Balance sheet Will it survive? 12/25

Debt / equity unknown 3/10

Current ratio 1.4 2/8

Free cash flow $1.4B 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for BHC — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-08-04. Research only — not financial advice.